Personalis

Yahoo Finance • last month

Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares

What happened According to an SEC filing dated February 17, 2026, Lightspeed Management Company, L.L.C. initiated a new position in Navan(NASDAQ:NAVN), acquiring 49,921,454 shares. The quarter-end value of the NAVN position stood at $852.... Full story

Yahoo Finance • 2 months ago

AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares

On February 2, 2026, AIGH Capital Management LLC fully exited its stake in MaxLinear(NASDAQ:MXL), selling 1,107,504 shares in a transaction estimated at $17.81 million based on quarterly average pricing. What happened According to a Secu... Full story

Yahoo Finance • 3 months ago

Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL)

Personalis, Inc. (NASDAQ:PSNL) is among the 12 Best Genomics Stocks to Invest In.Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titc... Full story

Yahoo Finance • 5 months ago

Personalis narrows 2025 revenue outlook to $68M-$73M amid biopharma project delays and rapid clinical test growth

Earnings Call Insights: Personalis, Inc. (PSNL) Q3 2025 MANAGEMENT VIEW * CEO Christopher Hall highlighted, "Q3 was another step forward in our Win-in-MRD strategy. We delivered 4,388 clinical tests, a 26% sequential and 364% year-over... Full story

Yahoo Finance • 6 months ago

Dexcom Appoints Euan Ashley to Board of Directors

SAN DIEGO, October 27, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renow... Full story

Yahoo Finance • 6 months ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

FREMONT, Calif., October 16, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings d... Full story

Yahoo Finance • 7 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

FREMONT, Calif., September 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The find... Full story

Yahoo Finance • 8 months ago

Personalis gains as VA awards work order worth up to $13.5M

[America / United States Department of Veterans Affairs.] Kiyoshi Tanno Shares of Personalis (NASDAQ:PSNL [https://seekingalpha.com/symbol/PSNL]) added ~5% in the premarket on Friday after the cancer test maker announced that it received... Full story

Yahoo Finance • 8 months ago

Cathie Wood's ARK ETFs make major buys in Deere & Co, Exact Sciences stock

Cathie Wood’s ARK ETF published their daily trades for Thursday, 14th August 2025, revealing a series of significant stock purchases across various sectors. Topping the list in dollar value was the acquisition of 64,789 shares of DEERE & C... Full story

Yahoo Finance • 8 months ago

Cathie Wood's ARK makes major moves in Trade Desk and Block stock

Cathie Wood’s ARK ETFs have once again made significant trades on Tuesday, 12 August 2025, with a major focus on tech and biotech stocks. The most substantial trade of the day was the purchase of 738,367 shares of Trade Desk Inc (NASDAQ:... Full story

Yahoo Finance • 8 months ago

Personalis outlines $70M–$80M revenue target for 2025 amid 59% sequential clinical test growth and revised biopharma outlook

Earnings Call Insights: Personalis, Inc. (PSNL) Q2 2025 MANAGEMENT VIEW * Christopher M. Hall, CEO, stated the quarter was marked by "outstanding execution of our win in MRD strategy," highlighting that "clinical adoption of NeXT Perso... Full story

Yahoo Finance • 9 months ago

Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes it to our list of the Top 10 AI Infrastructure Stocks to Buy Now.Tempus AI, Inc. (TEM) and Personalis Join Forces... Full story

Yahoo Finance • 9 months ago

Personalis extends Tempus agreement to add colorectal cancer indication

Personalis, Inc. (NASDAQ:PSNL), a medical laboratory services company with a market capitalization of $625 million and impressive revenue growth of 15.6% over the last twelve months, announced Tuesday that it has amended its existing comme... Full story

Yahoo Finance • 2 years ago

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc., a leader in advanced genomics for precision oncology, (... Full story

Yahoo Finance • 3 years ago

Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics

Infringed patents part of industry-leading intellectual property position in whole genome, tumor-informed minimal residual disease testing FREMONT, Calif., June 26, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced th... Full story

Yahoo Finance • 3 years ago

Dr. Kenneth J. Widder Joins Personalis Board of Directors

FREMONT, Calif., June 13, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporatio... Full story

Yahoo Finance • 3 years ago

Q1 2023 Personalis Inc Earnings Call

Participants Aaron L. Tachibana; CFO & COO; Personalis, Inc. Caroline V. Corner; MD; Westwicke Partners, LLC Christopher M. Hall; President, CEO & Director; Personalis, Inc. Richard Chen; Executive VP of R&D and Chief Medical Officer;... Full story

Yahoo Finance • 3 years ago

Personalis to Announce First Quarter 2023 Financial Results

FREMONT, Calif., April 19, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 202... Full story

Yahoo Finance • 3 years ago

Q4 2022 Personalis Inc Earnings Call

Participants Aaron L. Tachibana; Interim CEO & CFO; Personalis, Inc. Chris Hall Richard Chen; Senior VP of R&D and Chief Medical Officer; Personalis, Inc. Unidentified Analyst Vivien Bias Caroline V. Corner; MD; Westwicke Partners, L... Full story

Yahoo Finance • 3 years ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

FREMONT, Calif., January 04, 2023--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31,... Full story